COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01764841




Registration number
NCT01764841
Ethics application status
Date submitted
8/01/2013
Date registered
10/01/2013
Date last updated
24/01/2018

Titles & IDs
Public title
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Scientific title
Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.
Secondary ID [1] 0 0
2011-004208-39
Secondary ID [2] 0 0
15625
Universal Trial Number (UTN)
Trial acronym
RESPIRE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bronchiectasis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ciprofloxacin DPI (BAYQ3939)
Treatment: Drugs - Placebo

Experimental: Ciprofloxacin DPI 28 Days on/off (Cipro 28) - Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).

Experimental: Ciprofloxacin DPI 14 Days on/off (Cipro 14) - Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).

Placebo Comparator: Placebo 28 Days on/off (Placebo 28) - Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).

Placebo Comparator: Placebo 14 Days on/off (Placebo 14) - Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).


Treatment: Drugs: Ciprofloxacin DPI (BAYQ3939)
Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

Treatment: Drugs: Placebo
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to First Exacerbation Event Within 48 Weeks - Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms.
Timepoint [1] 0 0
Up to Week 48
Secondary outcome [1] 0 0
Number of Participants With Exacerbation Events With Worsening of at Least Three Signs/Symptoms Over 48 Weeks - For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks.
Timepoint [1] 0 0
Up to Week 48
Secondary outcome [2] 0 0
Number of Participants With Exacerbation Events With Worsening of at Least One Sign/Symptom Over 48 Weeks - For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks.
Timepoint [2] 0 0
Up to Week 48
Secondary outcome [3] 0 0
Percentage of Participants With Pathogen Eradication at End of Treatment (Week 44/46) - Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely.
Timepoint [3] 0 0
End of treatment (Week 44/46)
Secondary outcome [4] 0 0
Mean Change From Baseline in Patient Reported Outcome Saint George's Respiratory Questionnaire (SGRQ) Symptoms Component Score at End of Treatment (Week 44/46) - The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported.
Timepoint [4] 0 0
Baseline and end of treatment (Week 44/46)
Secondary outcome [5] 0 0
Percentage of Participants With Occurrence of New Pathogens Present at End of Treatment (Week 44/46) - New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely.
Timepoint [5] 0 0
End of treatment (Week 44/46)
Secondary outcome [6] 0 0
Mean Change From Baseline in Patient Reported Outcome Quality of Life Questionnaire for Bronchiectasis (QoL-B) Respiratory Symptoms Domain Score at End of Treatment (Week 44/46) - The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported.
Timepoint [6] 0 0
Baseline and end of treatment (Week 44/46)
Secondary outcome [7] 0 0
Mean Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at End of Treatment (Week 44/46) - FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS).
Timepoint [7] 0 0
Baseline and end of treatment (Week 44/46)

Eligibility
Key inclusion criteria
- Patients with a proven and documented diagnosis of non Cystic Fibrosis (CF) idiopathic
or post infectious bronchiectasis

- Stable pulmonary status and stable regimen of standard treatment at least for the past
4 weeks
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted

- Active allergic bronchopulmonary aspergillosis

- Active and actively treated non tuberculosis mycobacterial (NTM) infection or
tuberculosis

- Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
- Woolloongabba
Recruitment hospital [2] 0 0
- Adelaide
Recruitment hospital [3] 0 0
- Woodville
Recruitment hospital [4] 0 0
- Parkville
Recruitment hospital [5] 0 0
- Prahran
Recruitment hospital [6] 0 0
- Murdoch
Recruitment hospital [7] 0 0
- Box Hill
Recruitment hospital [8] 0 0
- Cairns
Recruitment hospital [9] 0 0
- Frankston
Recruitment hospital [10] 0 0
- Kogarah
Recruitment hospital [11] 0 0
- Toorak Gardens
Recruitment postcode(s) [1] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
5041 - Adelaide
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment postcode(s) [6] 0 0
3181 - Prahran
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
3128 - Box Hill
Recruitment postcode(s) [9] 0 0
4870 - Cairns
Recruitment postcode(s) [10] 0 0
3199 - Frankston
Recruitment postcode(s) [11] 0 0
2217 - Kogarah
Recruitment postcode(s) [12] 0 0
5065 - Toorak Gardens
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
District of Columbia
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
Argentina
State/province [21] 0 0
Ciudad Auton. De Buenos Aires
Country [22] 0 0
Argentina
State/province [22] 0 0
Mendoza
Country [23] 0 0
Argentina
State/province [23] 0 0
Vicente López
Country [24] 0 0
Denmark
State/province [24] 0 0
Aarhus C
Country [25] 0 0
Denmark
State/province [25] 0 0
Hellerup
Country [26] 0 0
Denmark
State/province [26] 0 0
Naestved
Country [27] 0 0
Denmark
State/province [27] 0 0
Roskilde
Country [28] 0 0
France
State/province [28] 0 0
Clermont Ferrand
Country [29] 0 0
France
State/province [29] 0 0
Montpellier
Country [30] 0 0
France
State/province [30] 0 0
Nimes
Country [31] 0 0
France
State/province [31] 0 0
Toulon
Country [32] 0 0
Germany
State/province [32] 0 0
Baden-Württemberg
Country [33] 0 0
Germany
State/province [33] 0 0
Brandenburg
Country [34] 0 0
Germany
State/province [34] 0 0
Hessen
Country [35] 0 0
Germany
State/province [35] 0 0
Niedersachsen
Country [36] 0 0
Germany
State/province [36] 0 0
Rheinland-Pfalz
Country [37] 0 0
Germany
State/province [37] 0 0
Schleswig-Holstein
Country [38] 0 0
Germany
State/province [38] 0 0
Thüringen
Country [39] 0 0
Germany
State/province [39] 0 0
Berlin
Country [40] 0 0
Germany
State/province [40] 0 0
Hamburg
Country [41] 0 0
Israel
State/province [41] 0 0
Afula
Country [42] 0 0
Israel
State/province [42] 0 0
Ashkelon
Country [43] 0 0
Israel
State/province [43] 0 0
Beer Sheva
Country [44] 0 0
Israel
State/province [44] 0 0
Haifa
Country [45] 0 0
Israel
State/province [45] 0 0
Jerusalem
Country [46] 0 0
Israel
State/province [46] 0 0
Petah Tikva
Country [47] 0 0
Israel
State/province [47] 0 0
Ramat Gan
Country [48] 0 0
Israel
State/province [48] 0 0
Rehovot
Country [49] 0 0
Israel
State/province [49] 0 0
Tel Aviv
Country [50] 0 0
Italy
State/province [50] 0 0
Campania
Country [51] 0 0
Italy
State/province [51] 0 0
Friuli-Venezia Giulia
Country [52] 0 0
Italy
State/province [52] 0 0
Lazio
Country [53] 0 0
Italy
State/province [53] 0 0
Lombardia
Country [54] 0 0
Italy
State/province [54] 0 0
Puglia
Country [55] 0 0
Italy
State/province [55] 0 0
Sardegna
Country [56] 0 0
Italy
State/province [56] 0 0
Sicilia
Country [57] 0 0
Italy
State/province [57] 0 0
Toscana
Country [58] 0 0
Italy
State/province [58] 0 0
Veneto
Country [59] 0 0
Japan
State/province [59] 0 0
Ehime
Country [60] 0 0
Japan
State/province [60] 0 0
Ibaraki
Country [61] 0 0
Japan
State/province [61] 0 0
Kumamoto
Country [62] 0 0
Japan
State/province [62] 0 0
Mie
Country [63] 0 0
Japan
State/province [63] 0 0
Osaka
Country [64] 0 0
Japan
State/province [64] 0 0
Shizuoka
Country [65] 0 0
Japan
State/province [65] 0 0
Tokyo
Country [66] 0 0
Japan
State/province [66] 0 0
Fukuoka
Country [67] 0 0
Latvia
State/province [67] 0 0
Daugavpils
Country [68] 0 0
Latvia
State/province [68] 0 0
Jurmala
Country [69] 0 0
Latvia
State/province [69] 0 0
Kraslava
Country [70] 0 0
Latvia
State/province [70] 0 0
Riga
Country [71] 0 0
Latvia
State/province [71] 0 0
Talsu
Country [72] 0 0
New Zealand
State/province [72] 0 0
Auckland
Country [73] 0 0
New Zealand
State/province [73] 0 0
Christchurch
Country [74] 0 0
New Zealand
State/province [74] 0 0
Dunedin
Country [75] 0 0
New Zealand
State/province [75] 0 0
Hamilton
Country [76] 0 0
New Zealand
State/province [76] 0 0
Tauranga
Country [77] 0 0
New Zealand
State/province [77] 0 0
Wellington
Country [78] 0 0
Slovakia
State/province [78] 0 0
Bratislava
Country [79] 0 0
Slovakia
State/province [79] 0 0
Presov
Country [80] 0 0
Spain
State/province [80] 0 0
A Coruña
Country [81] 0 0
Spain
State/province [81] 0 0
Alicante
Country [82] 0 0
Spain
State/province [82] 0 0
Asturias
Country [83] 0 0
Spain
State/province [83] 0 0
Barcelona
Country [84] 0 0
Spain
State/province [84] 0 0
Madrid
Country [85] 0 0
Spain
State/province [85] 0 0
Cáceres
Country [86] 0 0
Spain
State/province [86] 0 0
Pontevedra
Country [87] 0 0
Spain
State/province [87] 0 0
Valencia
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Cambridgeshire
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Devon
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Dundee City
Country [91] 0 0
United Kingdom
State/province [91] 0 0
North Ireland
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Shropshire
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Tyne And Wear
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Londonderry
Country [95] 0 0
United Kingdom
State/province [95] 0 0
London
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bayer
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Novartis
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate if the time to first pulmonary exacerbation of
bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days
every other 28 days or for 14 days every other 14 days over 48 weeks.
Trial website
https://clinicaltrials.gov/show/NCT01764841
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications